Early clinical experience of a new heparinoid, ORG 10172, in prevention of deep venous thrombosis

Cade, J. F.; Wood, Morgan; Magnani, H.N.; Westlake, George W.

doi:10.1016/0049-3848(87)90312-4

Cited by 28 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The common conclusions of these trials could be the comment of Cade et al 25 (using three dosages of the…”

Section: Another Possible Approachmentioning

confidence: 96%

“…In column 3 (bladder washout during day 1) there was no difference in blood loss between the three different dosage groups. The higher dosage (750 U twice daily (bid)) was found to be effective and safe for prophylaxis by Cade et al 25 Anti-Xa was performed with a chromogenic method using ORG 10172 as a standard. Hbg: hemoglobin.…”

Section: Fig 4 Relationship Between Mean Anti-xa Plasma Levelsmentioning

confidence: 99%

See 1 more Smart Citation

Can the Bleeding Potential of Low Molecular Weight Heparins be Assessed and Minimized in Postsurgery Prophylaxis?

Toulemonde

1991

Semin Thromb Hemost

View full text Add to dashboard Cite

“…The common conclusions of these trials could be the comment of Cade et al 25 (using three dosages of the…”

Section: Another Possible Approachmentioning

confidence: 96%

Section: Fig 4 Relationship Between Mean Anti-xa Plasma Levelsmentioning

confidence: 99%

Can the Bleeding Potential of Low Molecular Weight Heparins be Assessed and Minimized in Postsurgery Prophylaxis?

Toulemonde

1991

Semin Thromb Hemost

View full text Add to dashboard Cite

“…Org 10172 consists of approximately 80% heparan sulphate, 10% dermatan sul phate, and small amounts (approximately 5% each) of chondroitin sulphate and a LMW heparin-like component with high af finity for AT-III. In animal models, Org 10172 has a favourable anti-thrombotic/ bleeding risk ratio compared to heparin [1], Org 10172 has been shown to be especially beneficial for those patients who simulta neously have a high risk for bleeding, as well as for the development of deep-venous thrombosis [2,3], As it is more likely that Org 10172 will be administered to elderly patients than to younger ones, it can be expected that concomitant use with other medications may frequently occur.…”

Section: Introductionmentioning

confidence: 99%

Interaction of the Combined Medication with the New Low-Molecular-Weight Heparinoid Lomoparan® (Org 10172) and Acenocoumarol

Jc¹,

Danhof

et al. 1990

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

A high intravenous dose of the low-molecular-weight heparinoid Lomoparan® (Org 10172) was administered to 6 healthy males in a steady state of anticoagulation (Thrombotest) by acenocoumarol. Prothrombin time, activated partial thromboplastin time and Stypven time were prolonged to a degree which was greater than that expected on the base of the summation of the effects by each drug alone. This effect was observed for a period of up to 1 h. The Thrombotest was affected for up to 5 h after the intravenous administration of Org 10172, therefore it is deemed unsuitable for monitoring the combined effects of these two anticoagulants during this period. Acenocoumarol did not affect the pharmacokinetic parameters of Org 10172 with the exception of a slight reduction of the clearance of plasma anti-Xa activity.

show abstract

“…Orgaran (Org 10172, low-molecular-weight heparinoid) has been shown to be effective in pre venting venous thrombosis in high-risk surgi cal patients without significant bleeding risk [7], Orgaran is a mixture of sulphated glycosaminoglycans derived from animal intestinal mucosa which consists mainly of heparan and dermatan sulphate [8]. It has a mean molecu lar weight of 6,000 and a specific activity of 15 anti-factor Xa units/mg as determined against the Third International Heparin Stan dard by chromogenic assay.…”

mentioning

confidence: 99%

Orgaran in the Prevention of Deep Vein Thrombosis in Stroke Patients

Turpie¹

1992

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

Venous thrombo-embolism is a common complication in patients with acute ischaemic stroke. Without prophylaxis, deep vein thrombosis occurs in 60-75% of patients with dense hemiplegia, usually in the paralyzed limb, and 1-2% suffer fatal pulmonary embolism. Orgaran (Org 10172, low-molecular-weight heparinoid) has been evaluated for the prevention of deep vein thrombosis in patients with acute ischaemic stroke in two studies. In a double-blind study, 75 patients were randomized to receive Orgaran (50 patients) in a loading dose of 1,000 anti-Xa units intravenously followed by 750 anti-Xa units subcutaneously 12-hourly or placebo (25 patients). Deep vein thrombosis occurred in 2 of 50 (4%) in the Orgaran group and 7 of 25 (28%) in the placebo group (p = 0.005). The corresponding rates for proximal deep vein thrombosis were 0 and 16%, respectively (p = 0.01). There was one major haemorrhage in the treated group and one minor haemorrhage in the placebo group. In the second study, the safety and efficacy of Orgaran was compared with unfractionated heparin in the prevention of deep vein thrombosis in a double-blind randomized trial. Eighty-seven patients with marked lower limb paralysis secondary to stroke were randomized to receive Orgaran (45 patients) in a dose of 750 anti-factor Xa units subcutaneously 12-hourly or unfractionated heparin (42 patients) in a dose of 5,000 units subcutaneously 12-hourly. Venous thrombosis occurred in 4 of 45 (8.9%) of the Orgaran group and 13 of 42 (31%) in the unfractionated heparin group (2p = 0.014). The corresponding rates for proximal vein thrombosis were 4.4 and 11.9%, respectively (2p = 0.255).(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Early clinical experience of a new heparinoid, ORG 10172, in prevention of deep venous thrombosis

Cited by 28 publications

References 12 publications

Can the Bleeding Potential of Low Molecular Weight Heparins be Assessed and Minimized in Postsurgery Prophylaxis?

Can the Bleeding Potential of Low Molecular Weight Heparins be Assessed and Minimized in Postsurgery Prophylaxis?

Interaction of the Combined Medication with the New Low-Molecular-Weight Heparinoid Lomoparan® (Org 10172) and Acenocoumarol

Orgaran in the Prevention of Deep Vein Thrombosis in Stroke Patients

Contact Info

Product

Resources

About